Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers

A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine

ClinicalTrials.gov ID: NCT00109330

Public ClinicalTrials.gov record NCT00109330. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Observer-blinded Randomised, Multi-centre Clinical Study of the Safety, Immunogenicity and Consistency of Three Manufacturing Lots of GSK Biologicals' Candidate Tdap Vaccine as Compared to a US-licensed Td Vaccine When Given as a Booster Dose to Healthy Adolescents (10-18 Years of Age)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the safety and immune response to GlaxoSmithKline Tdap vaccine compared to licensed Td vaccine when used as a booster in healthy adolescents (10-18 years of age).

Study identification

NCT ID
NCT00109330
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
4,116 participants

Conditions and interventions

Eligibility (public fields only)

Age range
10 Years to 18 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2002
Primary completion
Mar 31, 2004
Completion
Mar 31, 2004
Last update posted
Sep 8, 2016

2002 – 2004

United States locations

U.S. sites
44
U.S. states
20
U.S. cities
42
Facility City State ZIP Site status
GSK Investigational Site Mesa Arizona 85201
GSK Investigational Site Tempe Arizona 85282
GSK Investigational Site Jonesboro Arkansas 72401
GSK Investigational Site Little Rock Arkansas 72202
GSK Investigational Site Escondido California 92021
GSK Investigational Site Fullerton California 92835
GSK Investigational Site Redondo Beach California 90277
GSK Investigational Site Rolling Hills Est California 90274
GSK Investigational Site Torrance California 90502
GSK Investigational Site Yorba Linda California 92886
GSK Investigational Site Boulder Colorado 80304
GSK Investigational Site Centennial Colorado 80112
GSK Investigational Site Golden Colorado 80401
GSK Investigational Site Middletown Connecticut 06457
GSK Investigational Site Norwich Connecticut 06360
GSK Investigational Site Jacksonville Florida 32209
GSK Investigational Site Chicago Illinois 60614
GSK Investigational Site Bardstown Kentucky 40004
GSK Investigational Site New Bedford Maine 2740
GSK Investigational Site Boston Massachusetts 02115
GSK Investigational Site Boston Massachusetts 02130
GSK Investigational Site Milford Massachusetts 01757
GSK Investigational Site Woburn Massachusetts 01801
GSK Investigational Site Omaha Nebraska 68178
GSK Investigational Site Whitehouse Station New Jersey 08889
GSK Investigational Site Rochester New York 14620
GSK Investigational Site Stony Brook New York 11794
GSK Investigational Site Chapel Hill North Carolina 27514
GSK Investigational Site Durham North Carolina 27710
GSK Investigational Site Lumberton North Carolina 28358
GSK Investigational Site Akron Ohio 44308-1062
GSK Investigational Site Cleveland Ohio 44109
GSK Investigational Site University Heights Ohio 44118
GSK Investigational Site Pittsburgh Pennsylvania 15213-2583
GSK Investigational Site Pittsburgh Pennsylvania 15241
GSK Investigational Site Sellersville Pennsylvania 18960
GSK Investigational Site Kingsport Tennessee 37660
GSK Investigational Site Bryan Texas 77802
GSK Investigational Site Georgetown Texas 78626
GSK Investigational Site Houston Texas 77030
GSK Investigational Site Temple Texas 76508
GSK Investigational Site Salt Lake City Utah 84109
GSK Investigational Site West Jordan Utah 84084
GSK Investigational Site Norfolk Virginia 23510

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00109330, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 8, 2016 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00109330 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →